Patients who received ramucirumab with erlotinib similarly showed a longer PFS than the monotherapy group, suggesting initial targeting of VEGFR2 and EGFR pathways is a viable option for the NSCLC treatment [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.